<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Renal cell carcinoma with sarcomatoid features
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Renal cell carcinoma with sarcomatoid features
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Renal cell carcinoma with sarcomatoid features
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Ziad Bakouny, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Toni K Choueiri, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael B Atkins, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sonali M Shah, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 24, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H386840525">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Renal cell carcinoma (RCC) is divided into two major groups based on histology: clear cell or non-clear cell RCC (ie, RCC of variant histology). Clear cell and non-clear cell RCCs are distinguished using morphology, growth pattern, cell of origin, and, where they are known, underlying biological and clinical characteristics.
        </p>
        <p>
         Tumor dedifferentiation can develop in any RCC, independent of histology [
         <a href="#rid1">
          1
         </a>
         ]. Sarcomatoid dedifferentiation, the most common form of tumor dedifferentiation, consists of cell components that are spindled or otherwise resemble sarcoma cells [
         <a href="#rid1">
          1,2
         </a>
         ]. However, sarcomatoid RCC is not classified as a distinct tumor subtype because it can be seen in any histologic subtype of RCC [
         <a href="#rid1">
          1,2
         </a>
         ]. Rather, these tumors are characterized by distinct molecular and biologic characteristics, including clinical response to systemic therapies. (See
         <a class="medical medical_review" href="/z/d/html/2982.html" rel="external">
          "Epidemiology, pathology, and pathogenesis of renal cell carcinoma"
         </a>
         .)
        </p>
        <p>
         This topic will review the epidemiology, pathology, clinical presentation, and management of RCC with sarcomatoid features. The management of clear cell and non-clear cell RCC histologies are discussed in detail separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15719.html" rel="external">
          "Overview of the treatment of renal cell carcinoma"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2984.html" rel="external">
          "Systemic therapy of advanced clear cell renal carcinoma"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/96030.html" rel="external">
          "The treatment of advanced non-clear cell renal carcinoma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2432778842">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         RCC with sarcomatoid dedifferentiation occurs in approximately 5 to 15 percent of all patients with RCC [
         <a href="#rid3">
          3-7
         </a>
         ]. Most patients present between 54 and 63 years of age [
         <a href="#rid8">
          8
         </a>
         ]. Sarcomatoid RCCs occur more commonly in males than females [
         <a href="#rid8">
          8
         </a>
         ] and in patients of White ethnicity compared with those of Black or Hispanic ethnicity [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         The prevalence of RCC with sarcomatoid features also depends on the background histology and stage of disease:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Background histology
         </strong>
         – Among tumors with sarcomatoid dedifferentiation, a greater proportion arise in the background of clear cell RCC (70 percent), although it can also be found in non-clear cell histologies [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Among patients with clear cell RCC and non-clear cell histologies, sarcomatoid dedifferentiation occurs at the following frequencies [
         <a href="#rid3">
          3,4,6-8
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Clear cell histologies
         </strong>
         – 5 to 13 percent
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Non-clear cell histologies:
         </strong>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Papillary – 2 to 7 percent
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Chromophobe – 9 to 13 percent
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Unclassified – 11 to 26 percent
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Collecting duct – 29 percent
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Sarcomatoid dedifferentiation is extremely rare in translocation RCCs, a subtype of non-clear cell tumors [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stage
         </strong>
         – RCC with sarcomatoid features can occur in patients presenting at all stages of disease but are more common in patients with metastatic disease. In observational series, sarcomatoid features occur in up to 15 percent of patients with metastatic RCC [
         <a href="#rid4">
          4,5
         </a>
         ] and 5 to 6 percent of those with localized disease [
         <a href="#rid3">
          3,7
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2983.html" rel="external">
          "Clinical manifestations, evaluation, and staging of renal cell carcinoma", section on 'TNM staging system'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3120564676">
         <span class="h1">
          PATHOLOGIC FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pathologic features of RCC with sarcomatoid features, including histology and molecular alterations, are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2982.html" rel="external">
          "Epidemiology, pathology, and pathogenesis of renal cell carcinoma", section on 'Renal cell carcinoma with sarcomatoid features'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3924589968">
         <span class="h1">
          CLINICAL PRESENTATION AND STAGING
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with sarcomatoid RCC are more likely to present with locally advanced or metastatic disease than other RCC histologies due to the aggressive nature of the disease. Most patients (approximately 90 percent) are symptomatic at presentation. The most common presenting symptoms are flank or abdominal pain, hematuria, weight loss, anorexia, fatigue, and night sweats [
         <a href="#rid7">
          7,8,11
         </a>
         ].
        </p>
        <p>
         The clinical presentation and staging of sarcomatoid RCC are similar to other RCC histologies and are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2983.html" rel="external">
          "Clinical manifestations, evaluation, and staging of renal cell carcinoma", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1059136597">
         <span class="h1">
          TREATMENT OF LOCALIZED DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The general approach to treatment of localized (American Joint Committee on Cancer eighth edition stage I to III  (
         <a class="graphic graphic_table graphicRef110735" href="/z/d/graphic/110735.html" rel="external">
          table 1
         </a>
         )) sarcomatoid RCC is surgical resection, which offers the best chance of cure. However, the presence of sarcomatoid features (as detected on intraoperative frozen section or on preoperative biopsy) often warrants more aggressive surgical treatment, including radical nephrectomy and extended lymphadenectomy. Further details on the surgical management of sarcomatoid RCC are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2985.html" rel="external">
          "Definitive surgical management of renal cell carcinoma", section on 'Radical nephrectomy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2985.html" rel="external">
          "Definitive surgical management of renal cell carcinoma", section on 'Retroperitoneal lymph nodes'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2042470637">
         <span class="h1">
          TREATMENT OF METASTATIC DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approximately 50 percent or more of patients with sarcomatoid RCC present with locally advanced, unresectable or metastatic disease, compared with just 15 percent of all patients with RCC [
         <a href="#rid6">
          6,7,11
         </a>
         ]. Common sites of metastatic disease in patients with sarcomatoid RCC include lungs, bone, lymph nodes, liver, and brain [
         <a href="#rid8">
          8
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2983.html" rel="external">
          "Clinical manifestations, evaluation, and staging of renal cell carcinoma", section on 'Symptoms and signs'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2341035909">
         <span class="h2">
          Initial therapy (clear cell RCC with sarcomatoid features)
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are limited high-quality data on the efficacy of systemic therapies for patients with metastatic sarcomatoid RCC due to the rarity of these tumors. Most evidence is based on subgroup analyses of randomized clinical trials and observational studies. As an example, one meta-analysis of four randomized clinical trials suggested that regimens containing checkpoint inhibitor immunotherapy demonstrate exceptional clinical efficacy in those with sarcomatoid RCC [
         <a href="#rid12">
          12
         </a>
         ]. By contrast, patients with sarcomatoid RCCs respond poorly to antiangiogenic or targeted therapies such as vascular endothelial growth factor receptor (VEGFR) or mechanistic target of rapamycin (mTOR) inhibitors.
        </p>
        <p class="headingAnchor" id="H412127592">
         <span class="h3">
          Nivolumab plus ipilimumab (preferred)
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with treatment-naïve metastatic clear cell RCC with sarcomatoid features, we recommend
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         (
         <a class="graphic graphic_table graphicRef139979" href="/z/d/graphic/139979.html" rel="external">
          table 2
         </a>
         ) rather than
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         . Nivolumab plus ipilimumab results in high complete response rates, improves long-term overall survival (OS), and offers most patients the opportunity for treatment-free survival. (See
         <a class="medical medical_review" href="/z/d/html/2984.html" rel="external">
          "Systemic therapy of advanced clear cell renal carcinoma", section on 'Nivolumab plus ipilimumab'
         </a>
         .)
        </p>
        <p>
         This combination is approved by the US Food and Drug Administration (FDA) for the initial treatment of patients with intermediate- and poor-risk metastatic clear cell RCC based on the International Metastatic RCC Database Consortium (IMDC) criteria  (
         <a class="graphic graphic_table graphicRef116130" href="/z/d/graphic/116130.html" rel="external">
          table 3
         </a>
         ). Most patients with sarcomatoid RCC typically present with intermediate- and poor-risk disease and thus are eligible for this therapy. We also offer this combination in patients with sarcomatoid RCC and favorable-risk disease because of the high rate of durable complete responses with this therapy, although such tumors are less common [
         <a href="#rid5">
          5
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2984.html" rel="external">
          "Systemic therapy of advanced clear cell renal carcinoma", section on 'Nivolumab plus ipilimumab'
         </a>
         .)
        </p>
        <p>
         In patients with sarcomatoid tumors, the combination of
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         improves both OS and progression-free survival (PFS) over VEGFR inhibitor therapy based on data from a randomized phase III trial (CheckMate 214). In a post-hoc subset analysis of this study, 139 patients with intermediate- or poor-risk advanced RCC  (
         <a class="graphic graphic_table graphicRef116130" href="/z/d/graphic/116130.html" rel="external">
          table 3
         </a>
         ) with sarcomatoid features received either nivolumab plus ipilimumab followed by maintenance nivolumab  (
         <a class="graphic graphic_table graphicRef127100" href="/z/d/graphic/127100.html" rel="external">
          table 4
         </a>
         ), or
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         [
         <a href="#rid12">
          12-15
         </a>
         ]. At a minimum follow-up of five years, relative to sunitinib, the combination of nivolumab plus ipilimumab demonstrated the following, independent of tumor programmed cell death ligand 1 (PD-L1) status [
         <a href="#rid16">
          16
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Improved OS (five-year OS 47 versus 21 percent, median OS 49 versus 14 months, hazard ratio [HR] 0.46, 95% CI 0.29-0.71).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Improved PFS (five-year PFS 46 versus 12 percent, median PFS 27 versus 6 months, HR 0.5, 95% CI 0.32-0.8).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Higher objective (61 versus 23 percent) and complete (23 versus 6 percent) response rates.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment was well tolerated, with toxicity profiles similar to previously reported studies [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Further details regarding the administration of
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         , efficacy in patients with clear cell RCC based on IMDC subgroups, and expected toxicities are discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2984.html" rel="external">
          "Systemic therapy of advanced clear cell renal carcinoma", section on 'Nivolumab plus ipilimumab'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/96368.html" rel="external">
          "Toxicities associated with immune checkpoint inhibitors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3183918128">
         <span class="h3">
          Nivolumab plus cabozantinib
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with treatment-naïve metastatic sarcomatoid RCC,
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">
          cabozantinib
         </a>
         is an alternative to nivolumab plus
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         . Although nivolumab plus cabozantinib improved OS over single-agent
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         in this population [
         <a href="#rid17">
          17
         </a>
         ], longer follow-up is necessary to confirm these outcomes.
        </p>
        <p>
         The efficacy of
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">
          cabozantinib
         </a>
         over single-agent
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         was established in a randomized phase III trial (CheckMate 9ER) conducted in patients with treatment-naïve advanced clear cell RCC. Further details on this trial are discussed separately.(See
         <a class="medical medical_review" href="/z/d/html/2984.html" rel="external">
          "Systemic therapy of advanced clear cell renal carcinoma", section on 'Nivolumab plus cabozantinib'
         </a>
         .)
        </p>
        <p>
         At median follow-up of 18 months, in preliminary results from the subset of 75 patients with sarcomatoid features,
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">
          cabozantinib
         </a>
         improved PFS (median 11 versus 4 months, HR 0.39, 95% CI 0.22-0.7), OS (median not reached versus 20 months, HR 0.36, 95% CI 0.16-0.82), and objective response rates (ORR; 56 versus 22 percent) relative to
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2046018846">
         <span class="h3">
          Pembrolizumab plus axitinib
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with treatment-naïve metastatic sarcomatoid RCC,
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         (
         <a class="graphic graphic_table graphicRef127101" href="/z/d/graphic/127101.html" rel="external">
          table 5
         </a>
         ) plus
         <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">
          axitinib
         </a>
         is an alternative to
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         . However, an OS advantage has not been established in this population.
        </p>
        <p>
         The efficacy of
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">
          axitinib
         </a>
         over single-agent
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         was established in a randomized phase III trial (KEYNOTE-426) conducted in patients with treatment-naïve advanced clear cell RCC. Further details of this trial are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2984.html" rel="external">
          "Systemic therapy of advanced clear cell renal carcinoma", section on 'Pembrolizumab plus axitinib'
         </a>
         .)
        </p>
        <p>
         At median follow-up of 13 months, in preliminary results from a subset of 105 patients with advanced RCC with sarcomatoid features,
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">
          axitinib
         </a>
         improved ORR (59 versus 32 percent) and complete response rates (12 versus 0 percent) relative to
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         [
         <a href="#rid18">
          18
         </a>
         ]. While survival data are immature for those with advanced RCC with sarcomatoid features, there was a nonstatistically significant trend towards improved OS and PFS, which would be clinically meaningful if true (one-year OS 83 versus 80 percent, HR 0.58, 95% CI 0.21-1.59; one-year PFS 57 versus 26 percent, HR 0.54, 95% CI 0.29-1.00).
        </p>
        <p class="headingAnchor" id="H239609706">
         <span class="h3">
          Lenvatinib plus pembrolizumab
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with treatment-naïve metastatic sarcomatoid RCC,
         <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">
          lenvatinib
         </a>
         plus
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         is an alternative to
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         . However, an OS advantage has not been established in this population.
        </p>
        <p>
         The efficacy of
         <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">
          lenvatinib
         </a>
         plus
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         over single-agent
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         was established a randomized phase III trial (CLEAR) conducted in patients with treatment-naïve metastatic clear cell RCC. Further details of this trial are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2984.html" rel="external">
          "Systemic therapy of advanced clear cell renal carcinoma", section on 'Lenvatinib plus pembrolizumab'
         </a>
         .)
        </p>
        <p>
         At median follow-up of 27 months, in preliminary results from the subset of 49 patients with sarcomatoid features,
         <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">
          lenvatinib
         </a>
         plus
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         improved PFS (median PFS 11 versus 6 months, HR 0.39, 95% CI 0.18-0.84) and ORR (61 versus 24 percent) relative to
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         . OS was similar between the two treatment arms (median OS NE versus NE months, HR 0.91, 95% CI 0.32-2.58) [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4187302555">
         <span class="h3">
          Avelumab plus axitinib
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with treatment-naïve metastatic RCC, the combination of
         <a class="drug drug_general" data-topicid="112481" href="/z/d/drug information/112481.html" rel="external">
          avelumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">
          axitinib
         </a>
         is an appropriate alternative to
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         . However, an OS advantage has not been established in this population.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="112481" href="/z/d/drug information/112481.html" rel="external">
          Avelumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">
          axitinib
         </a>
         was compared with single-agent
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         in a randomized phase III trial (JAVELIN RENAL 101). Further details of this study are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2984.html" rel="external">
          "Systemic therapy of advanced clear cell renal carcinoma", section on 'Avelumab plus axitinib'
         </a>
         .)
        </p>
        <p>
         At a median follow-up of approximately 12 months, in preliminary results from the subset of 108 patients with sarcomatoid RCC,
         <a class="drug drug_general" data-topicid="112481" href="/z/d/drug information/112481.html" rel="external">
          avelumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">
          axitinib
         </a>
         improved PFS (median PFS 7 versus 4 months; HR 0.57, 95% CI 0.33-1.00), objective (47 versus 21 percent), and complete (4 versus 0 percent) response rates. OS data were not reported for the sarcomatoid subgroup [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3845261602">
         <span class="h3">
          Less preferred regimens
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other less preferred immunotherapy options for patients with metastatic sarcomatoid RCC include
         <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">
          atezolizumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         ,
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         (
         <a class="graphic graphic_table graphicRef127101" href="/z/d/graphic/127101.html" rel="external">
          table 5
         </a>
         ), or
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         (
         <a class="graphic graphic_table graphicRef127100" href="/z/d/graphic/127100.html" rel="external">
          table 4
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H320867113">
         <span class="h4">
          Atezolizumab plus bevacizumab
         </span>
         <span class="headingEndMark">
          —
         </span>
         The combination of
         <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">
          atezolizumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         is also active in those with sarcomatoid RCC [
         <a href="#rid21">
          21
         </a>
         ]. However, this combination does not have regulatory approval as initial therapy for advanced RCC, and its use remains investigational.
        </p>
        <p>
         Further details on
         <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">
          atezolizumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         for the treatment-naïve metastatic clear cell RCC are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2984.html" rel="external">
          "Systemic therapy of advanced clear cell renal carcinoma", section on 'Atezolizumab plus bevacizumab'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3786667995">
         <span class="h4">
          Pembrolizumab
         </span>
         <span class="headingEndMark">
          —
         </span>
         Single-agent
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         (
         <a class="graphic graphic_table graphicRef127101" href="/z/d/graphic/127101.html" rel="external">
          table 5
         </a>
         ) has clinical efficacy in metastatic clear cell RCC with sarcomatoid features, but its use remains investigational.
        </p>
        <p>
         The efficacy of single-agent
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         (
         <a class="graphic graphic_table graphicRef127101" href="/z/d/graphic/127101.html" rel="external">
          table 5
         </a>
         ) in sarcomatoid RCC was demonstrated in an open-label, nonrandomized phase II trial (KEYNOTE-427) consisting of two cohorts. Cohort A had 110 patients with treatment-naïve clear cell RCC, including 11 patients (10 percent) with sarcomatoid features [
         <a href="#rid22">
          22
         </a>
         ], and cohort B had 165 patients with non-clear cell RCC, including 38 (23 percent) with sarcomatoid features [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
         At median follow-up of 36 months, in the cohort A subset, the objective and complete response rates for
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         in those with sarcomatoid RCC were 64 and 0 percent, respectively (versus 42 and 8 percent for cohort B). Further results for cohort B are discussed separately. (See
         <a class="local">
          'Pembrolizumab'
         </a>
         below.)
        </p>
        <p>
         Further details from this study on the efficacy of
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         in advanced clear cell RCC are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2984.html" rel="external">
          "Systemic therapy of advanced clear cell renal carcinoma", section on 'Pembrolizumab'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1118797550">
         <span class="h2">
          Initial therapy (non-clear cell RCC with sarcomatoid features)
         </span>
        </p>
        <p class="headingAnchor" id="H1420138235">
         <span class="h3">
          Nivolumab plus ipilimumab
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with treatment-naïve non-clear cell RCC with sarcomatoid features, we suggest
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         rather than VEGFR inhibitors or
         <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">
          lenvatinib
         </a>
         plus
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         , based on observational studies [
         <a href="#rid24">
          24
         </a>
         ] and extrapolating from data in clear cell RCC with sarcomatoid features. (See
         <a class="local">
          'Nivolumab plus ipilimumab (preferred)'
         </a>
         above.)
        </p>
        <p>
         Sarcomatoid dedifferentiation can occur on a background of non-clear cell (or variant) histology RCC, including papillary, chromophobe, collecting duct, and translocation RCC. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
         In patients with non-clear cell RCC and sarcomatoid features, studies suggest that immunotherapy-based regimens are associated with improved OS relative to VEGFR inhibitors, although high-quality data are limited. As an example, one observational study evaluated initial therapy with immunotherapy-based regimens (including
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         ) versus VEGFR inhibitors (
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         or
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          pazopanib
         </a>
         ) in 103 patients with non-clear cell RCC and a sarcomatoid and/or rhabdoid component and 429 patients with non-clear cell RCC lacking a sarcomatoid and/or rhabdoid component [
         <a href="#rid24">
          24
         </a>
         ]. Approximately 70 percent of the patients received nivolumab plus ipilimumab, and 30 percent received immunotherapy plus VEGFR inhibitors.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In preliminary results for patients with sarcomatoid and/or rhabdoid non-clear cell RCC, relative to VEGFR inhibitors, immunotherapy-based regimens were associated with improved OS (median not reached versus 7 months, HR 0.25, 95% CI 0.13-0.49), PFS (median 9 versus 3 months, HR 0.34, 95% CI 0.21-0.59), and ORR (34 versus 11 percent). Time to treatment failure was also prolonged with immunotherapy-based regimens (9 versus 3 months).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         By contrast, among patients with non-clear cell RCC lacking a sarcomatoid and/or rhabdoid component, immunotherapy-based regimens were not associated with improved OS (median 24 versus 15 months, HR 0.74, 95% CI 0.46-1.21), PFS (median 4 versus 5 months, HR 1.2, 95% CI 0.85-1.71), or ORR (23 versus 18 percent). Time to treatment failure was similar between the treatment arms (4 versus 5 months).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2990670768">
         <span class="h3">
          Lenvatinib plus pembrolizumab
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">
          Lenvatinib
         </a>
         plus
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         is an alternative to
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         in patients with treatment-naïve metastatic sarcomatoid non-clear cell RCC. However, an OS advantage has not been established in this population.
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">
          Lenvatinib
         </a>
         plus
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         was evaluated in a single-arm phase II trial (KEYNOTE-B61) of 158 patients with treatment-naïve metastatic non-clear cell RCC [
         <a href="#rid25">
          25
         </a>
         ]. At a median follow-up of 15 months, in the subset of 19 patients with sarcomatoid features, the ORR was 47 percent.
        </p>
        <p>
         Further details on the efficacy of
         <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">
          lenvatinib
         </a>
         plus
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         in patients with advanced clear cell RCC are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2984.html" rel="external">
          "Systemic therapy of advanced clear cell renal carcinoma", section on 'Lenvatinib plus pembrolizumab'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3776344225">
         <span class="h3">
          Less preferred regimens
         </span>
        </p>
        <p class="headingAnchor" id="H3731176901">
         <span class="h4">
          Atezolizumab plus bevacizumab
         </span>
         <span class="headingEndMark">
          —
         </span>
         The combination of
         <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">
          atezolizumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         is also active in those with non-clear cell RCC with a sarcomatoid component [
         <a href="#rid26">
          26
         </a>
         ]. However, this combination does not have regulatory approval as initial therapy for advanced RCC, and its use remains investigational.
        </p>
        <p>
         Further data on the efficacy of
         <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">
          atezolizumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         in patients with advanced clear cell RCC are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2984.html" rel="external">
          "Systemic therapy of advanced clear cell renal carcinoma", section on 'Atezolizumab plus bevacizumab'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2617240931">
         <span class="h4">
          Nivolumab plus ipilimumab and cabozantinib
         </span>
         <span class="headingEndMark">
          —
         </span>
         The combination of
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         and
         <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">
          cabozantinib
         </a>
         is active in those with non-clear cell RCC with a sarcomatoid component [
         <a href="#rid27">
          27
         </a>
         ]. The use of this combination remains investigational.
        </p>
        <p>
         Further details on this combination in patients with advanced clear cell RCC are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2984.html" rel="external">
          "Systemic therapy of advanced clear cell renal carcinoma", section on 'Nivolumab plus ipilimumab and cabozantinib'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2980186506">
         <span class="h4">
          Pembrolizumab
         </span>
         <span class="headingEndMark">
          —
         </span>
         Single-agent
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         (
         <a class="graphic graphic_table graphicRef127101" href="/z/d/graphic/127101.html" rel="external">
          table 5
         </a>
         ) has clinical efficacy in metastatic non-clear cell RCC with sarcomatoid features, but its use remains investigational.
        </p>
        <p>
         The efficacy of single-agent
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         (
         <a class="graphic graphic_table graphicRef127101" href="/z/d/graphic/127101.html" rel="external">
          table 5
         </a>
         ) in sarcomatoid RCC was demonstrated in an open-label, nonrandomized phase II trial (KEYNOTE-427) consisting of two cohorts. Cohort A had 110 patients with treatment-naïve clear cell RCC, including 11 patients (10 percent) with sarcomatoid features, [
         <a href="#rid22">
          22
         </a>
         ] and cohort B had 165 patients with non-clear cell RCC, including 38 (23 percent) with sarcomatoid features [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
         At median follow-up of 32 months, in the cohort B subset, objective and complete response rates for
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         in those with sarcomatoid RCC were 42 and 8 percent, respectively (versus 64 and 0 percent in cohort A). Further results for cohort A are discussed separately. (See
         <a class="local">
          'Pembrolizumab'
         </a>
         above.)
        </p>
        <p>
         Further details from this study on the efficacy of
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         in other non-clear cell histologies are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/96030.html" rel="external">
          "The treatment of advanced non-clear cell renal carcinoma", section on 'Pembrolizumab'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H623815061">
         <span class="h2">
          Ineligible for immunotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with RCC with sarcomatoid features arising from either clear cell or non-clear histologies who are not eligible for immunotherapy-based regimens, we offer antiangiogenic therapy with VEGFR inhibitors rather than chemotherapy, although this approach has limited efficacy in those with sarcomatoid features. The choice of VEGFR inhibitors in this population is similar to their use in those with clear cell RCC. (See
         <a class="medical medical_review" href="/z/d/html/2984.html" rel="external">
          "Systemic therapy of advanced clear cell renal carcinoma", section on 'Ineligible for immunotherapy (intermediate- and poor-risk)'
         </a>
         .)
        </p>
        <p>
         One observational series derived from the IMDC identified 230 patients with sarcomatoid features [
         <a href="#rid28">
          28
         </a>
         ]. Among the approximately 93 percent of patients treated with VEGFR-directed therapy as initial therapy, the overall response rate was 21 percent; median PFS and OS were 5 and 10 months, respectively. Similar objective response rates for single-agent
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         were seen in a randomized trial [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
         The effectiveness of mTOR inhibitors for the treatment of sarcomatoid RCC is also limited [
         <a href="#rid4">
          4,5
         </a>
         ]. Although mTOR inhibitors are approved for the treatment of metastatic RCC, immunotherapy-based regimens should be preferred whenever possible for sarcomatoid RCC. (See
         <a class="medical medical_review" href="/z/d/html/2962.html" rel="external">
          "Antiangiogenic and molecularly targeted therapy for advanced or metastatic clear cell renal carcinoma", section on 'Inhibitors of the mTOR pathway'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1720860275">
         <span class="h2">
          Is there a role for other approaches?
         </span>
        </p>
        <p class="headingAnchor" id="H2370717899">
         <span class="h3">
          Cytoreductive nephrectomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         We do not offer upfront cytoreductive nephrectomy in patients with sarcomatoid RCC, as data suggest poor outcomes with this approach [
         <a href="#rid30">
          30
         </a>
         ]. Upfront cytoreductive nephrectomy is preferred in patients with good performance status, and low disease burden; patients with sarcomatoid RCC are less likely to meet these criteria. Alternatively, select patients with sarcomatoid RCC and a deep partial or complete response of disease outside the kidney to initial systemic immunotherapy could subsequently be offered cytoreductive nephrectomy and surgical resection of residual sites of metastatic disease. (See
         <a class="medical medical_review" href="/z/d/html/2963.html" rel="external">
          "Role of surgery in patients with metastatic renal cell carcinoma", section on 'Cytoreductive nephrectomy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3625327923">
         <span class="h3">
          Chemotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no established role for cytotoxic chemotherapy alone or in combination with targeted therapy in those with RCC with sarcomatoid features. As an example, some studies demonstrated clinical activity for the combination of
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         and
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         in patients with RCC with sarcomatoid features [
         <a href="#rid31">
          31
         </a>
         ], but data overall has not consistently shown clinical efficacy for this approach [
         <a href="#rid32">
          32-36
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1708147452">
         <span class="h3">
          Active surveillance
         </span>
         <span class="headingEndMark">
          —
         </span>
         Active surveillance is generally reserved for patients with IMDC favorable-risk disease  (
         <a class="graphic graphic_table graphicRef116130" href="/z/d/graphic/116130.html" rel="external">
          table 3
         </a>
         ) who are asymptomatic or minimally symptomatic and have a low disease burden. Active surveillance is not typically offered to those with sarcomatoid RCC because they are unlikely to fit these criteria. (See
         <a class="medical medical_review" href="/z/d/html/2984.html" rel="external">
          "Systemic therapy of advanced clear cell renal carcinoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4156613131">
         <span class="h2">
          Subsequent therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our approach to subsequent therapy in patients with metastatic sarcomatoid RCC depends on the choice of initial therapy. Clinical trials are encouraged where available, given the rarity of these tumors. Our approach is as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Progression on
         </strong>
         <strong>
          nivolumab
         </strong>
         <strong>
          plus
         </strong>
         <strong>
          ipilimumab
         </strong>
         – For patients who progress on initial treatment with
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         , we offer an antiangiogenic agent rather than the combination of immunotherapy plus antiangiogenic agent. In a randomized trial (CONTACT-03), the latter approach did not improve PFS or OS and increased toxicity relative to antiangiogenic therapy alone, including in the subgroup of patients with sarcomatoid features arising from either clear cell or non-clear cell RCC [
         <a href="#rid37">
          37
         </a>
         ]. Selection of therapy and further details on this trial are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2984.html" rel="external">
          "Systemic therapy of advanced clear cell renal carcinoma", section on 'Prior immunotherapy with or without antiangiogenic therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Progression on combined immunotherapy plus VEGFR inhibitor
         </strong>
         – For those who progress on immunotherapy plus VEGFR inhibition, either in combination or via sequential use of these agents, we prefer
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         (
         <a class="graphic graphic_table graphicRef139979" href="/z/d/graphic/139979.html" rel="external">
          table 2
         </a>
         ). Other options include antiangiogenic therapy not previously received, such as single-agent
         <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">
          cabozantinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="131053" href="/z/d/drug information/131053.html" rel="external">
          tivozanib
         </a>
         , or
         <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">
          lenvatinib
         </a>
         plus
         <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">
          everolimus
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/2984.html" rel="external">
          "Systemic therapy of advanced clear cell renal carcinoma", section on 'Prior immunotherapy with or without antiangiogenic therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          No prior immunotherapy
         </strong>
         – For those who have not yet received immunotherapy (eg, those previously treated with VEGFR inhibitors alone), we offer immunotherapy-based regimens. Our preferred regimen is
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         (
         <a class="graphic graphic_table graphicRef139979" href="/z/d/graphic/139979.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Initial therapy (clear cell RCC with sarcomatoid features)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H669223127">
         <span class="h1">
          ASSESSMENT OF TREATMENT RESPONSE
         </span>
         <span class="headingEndMark">
          —
         </span>
         We assess the treatment response of patients with sarcomatoid RCC as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For most patients, we obtain computed tomography (CT) imaging of the chest and abdomen (with or without pelvic imaging) every two to three months. Brain imaging (eg, magnetic resonance imaging or CT brain) may be obtained as clinically indicated (ie, based on neurologic symptoms). However, since sarcomatoid histology appears to be a risk factor for developing brain metastases, it is also reasonable to offer surveillance brain imaging in asymptomatic patients with metastatic disease [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with clinically aggressive disease at baseline, we image more frequently with CT chest, abdomen, pelvis, and brain imaging every six to eight weeks.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with prolonged deep partial (ie, greater than 80 percent regression of disease outside the kidney) or complete responses to immune checkpoint inhibitor-based regimens, we reduce the frequency of imaging to every four months to six months, depending upon the duration of response. (See
         <a class="medical medical_review" href="/z/d/html/99637.html" rel="external">
          "Principles of cancer immunotherapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3437466694">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Historically, the prognosis of patients with advanced, unresectable, or metastatic sarcomatoid RCC has been poor and treatment has been palliative. Sarcomatoid RCC is associated with limited responsiveness to targeted therapies, such as vascular endothelial growth factor receptor inhibitors or mechanistic target of rapamycin inhibitors [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         However, both the prognosis and treatment of these patients are evolving in the era of checkpoint inhibitor immunotherapy, and some of these patients may have durable responses. Sarcomatoid RCC generally responds better to immunotherapy-based regimens than nonsarcomatoid RCC, regardless of background histology (ie, clear cell versus non-clear cell). There is currently no evidence that background histology alters management. In patients with sarcomatoid RCC, immunotherapy extends median overall survival to over three years and improves complete response rates, suggesting the potential for cure.
        </p>
        <p class="headingAnchor" id="H3545466186">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/119821.html" rel="external">
          "Society guideline links: Cancer of the kidney and ureters"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1085722188">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15490.html" rel="external">
          "Patient education: Kidney cancer (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/888.html" rel="external">
          "Patient education: Renal cell carcinoma (kidney cancer) (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3131583752">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sarcomatoid dedifferentiation
         </strong>
         – Sarcomatoid dedifferentiation is the most common form of tumor dedifferentiation in renal cell carcinoma (RCC) and can be seen in both clear cell and non-clear cell histologies. (See
         <a class="local">
          'Epidemiology'
         </a>
         above and
         <a class="local">
          'Pathologic features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentation
         </strong>
         – Patients with sarcomatoid RCC typically present with locally advanced or metastatic disease. The most common presenting symptoms are flank or abdominal pain, hematuria, weight loss, anorexia, fatigue, and night sweats. (See
         <a class="local">
          'Clinical presentation and staging'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment of localized disease
         </strong>
         – Patients with localized sarcomatoid RCC are treated with surgical resection. However, the presence of sarcomatoid features often warrants more aggressive surgical treatment, including radical nephrectomy and extended lymphadenectomy. (See
         <a class="medical medical_review" href="/z/d/html/2985.html" rel="external">
          "Definitive surgical management of renal cell carcinoma", section on 'Radical nephrectomy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2985.html" rel="external">
          "Definitive surgical management of renal cell carcinoma", section on 'Retroperitoneal lymph nodes'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial therapy for
         </strong>
         <strong>
          advanced or metastatic disease
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Clear cell RCC with sarcomatoid features
         </strong>
         – For patients with treatment-naïve advanced or metastatic clear cell RCC with sarcomatoid features, we recommend
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         (
         <a class="graphic graphic_table graphicRef139979" href="/z/d/graphic/139979.html" rel="external">
          table 2
         </a>
         ) rather than
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         as initial therapy (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). Nivolumab plus ipilimumab results in high complete response rates, improves long-term overall survival (OS), and offers most patients the opportunity for treatment-free survival. (See
         <a class="local">
          'Nivolumab plus ipilimumab (preferred)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Alternative options to
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         include combination immunotherapy plus antiangiogenic therapy, although an OS advantage has not been established. Available regimens include nivolumab plus
         <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">
          cabozantinib
         </a>
         ;
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">
          axitinib
         </a>
         ;
         <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">
          lenvatinib
         </a>
         plus pembrolizumab; or
         <a class="drug drug_general" data-topicid="112481" href="/z/d/drug information/112481.html" rel="external">
          avelumab
         </a>
         plus axitinib.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Non-clear cell RCC with sarcomatoid features
         </strong>
         – For patients with treatment-naïve non-clear cell RCC and sarcomatoid features, we suggest
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         rather than vascular endothelial growth factor receptor (VEGFR) inhibitors or
         <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">
          lenvatinib
         </a>
         plus
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ) based on observational studies in this population suggesting an OS advantage and extrapolating from data in clear cell RCC with sarcomatoid features. (See
         <a class="local">
          'Nivolumab plus ipilimumab'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">
          Lenvatinib
         </a>
         plus
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         is also an appropriate alternative, although an OS advantage has not been established. (See
         <a class="local">
          'Lenvatinib plus pembrolizumab'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Ineligible for immunotherapy
         </strong>
         – For those with sarcomatoid features arising from either clear or non-clear histologies who are not eligible for immunotherapy, we offer antiangiogenic therapy with VEGFR inhibitors rather than chemotherapy, although this approach has limited efficacy in those with sarcomatoid features. The use of VEGFR inhibitors in this population is similar to their use in those with clear cell RCC. (See
         <a class="medical medical_review" href="/z/d/html/2984.html" rel="external">
          "Systemic therapy of advanced clear cell renal carcinoma", section on 'Ineligible for immunotherapy (intermediate- and poor-risk)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Assessment of treatment response
         </strong>
         – For most patients, we assess treatment response using CT imaging of the chest and abdomen (with or without pelvic imaging) every two to three months. We obtain brain imaging (eg, magnetic resonance imaging or CT brain) as clinically indicated (ie, based on neurologic symptoms). However, it is reasonable also to offer surveillance brain imaging in asymptomatic patients with metastatic disease since sarcomatoid histology appears to be a risk factor for developing brain metastases. (See
         <a class="local">
          'Assessment of treatment response'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          WHO classification of tumours of the urinary system and male genital organs, Moch H, Humphrey PA, Ulbright TM, Reuter VE (Eds), World Health Organization, Lyon 2016.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delahunt B, Cheville JC, Martignoni G, et al. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol 2013; 37:1490.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amin MB, Amin MB, Tamboli P, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol 2002; 26:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bakouny Z, Braun DA, Shukla SA, et al. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nat Commun 2021; 12:808.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kyriakopoulos CE, Chittoria N, Choueiri TK, et al. Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Clin Genitourin Cancer 2015; 13:e79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Peralta-Venturina M, Moch H, Amin M, et al. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol 2001; 25:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheville JC, Lohse CM, Zincke H, et al. Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol 2004; 28:435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blum KA, Gupta S, Tickoo SK, et al. Sarcomatoid renal cell carcinoma: biology, natural history and management. Nat Rev Urol 2020; 17:659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adibi M, Thomas AZ, Borregales LD, et al. Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation. Urol Oncol 2015; 33:427.e17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caliò A, Segala D, Munari E, et al. MiT Family Translocation Renal Cell Carcinoma: from the Early Descriptions to the Current Knowledge. Cancers (Basel) 2019; 11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mian BM, Bhadkamkar N, Slaton JW, et al. Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J Urol 2002; 167:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iacovelli R, Ciccarese C, Bria E, et al. Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors. Eur J Cancer 2020; 136:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med 2018; 378:1277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol 2019; 20:1370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tannir NM, Signoretti S, Choueiri TK, et al. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. Clin Cancer Res 2021; 27:78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rini BI, Signoretti S, Choueiri TK, et al. Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma. J Immunother Cancer 2022; 10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Motzer RJ, Choueiri TK, Powles T, et al. Nivolumab + cabozantinib (NIVO+CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER. J Clin Oncol 2021; 39:308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rini BI, Plimack ER, Stus V, et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study. J Clin Oncol 2019; 15S.
          </a>
         </li>
         <li class="breakAll">
          Choueiri TK, Eto M, Kopyltsov E, et al. 660P - Phase III CLEAR trial in advanced renal cell carcinoma (aRCC): Outcomes in subgroups and toxicity update. Poster, ESMO Congress 2021, Paris, France September 2021.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choueiri TK, Larkin JMG, Pal SK, et al. Efficacy and biomarker analysis of patients (pts) with advanced renal cell carcinoma (aRCC) with sarcomatoid histology (sRCC): Subgroup analysis from the phase III JAVELIN renal 101 trial of first-line avelumab plus axitinib (A + Ax) vs sunitinib (S). Ann Oncol 2019; 30:v361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rini BI, Motzer RJ, Powles T, et al. Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial. Eur Urol 2021; 79:659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDermott DF, Lee JL, Bjarnason GA, et al. Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma. J Clin Oncol 2021; 39:1020.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDermott DF, Lee JL, Ziobro M, et al. Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma. J Clin Oncol 2021; 39:1029.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Labaki C, Bakouny Z, Lemelin A, et al. Efficacy of first-line (1L) immunotherapy (IO)-based regimens in patients with sarcomatoid and/or rhabdoid (S/R) metastatic non-clear cell renal cell carcinoma (nccRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). J Clin Oncol 2023; 41:4519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Albiges L, Gurney H, Atduev V, et al. Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial. Lancet Oncol 2023; 24:881.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGregor BA, McKay RR, Braun DA, et al. Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features. J Clin Oncol 2020; 38:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGregor BA, Huang J, Xie W, et al. Phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with variant histologies (RCCvh). J Clin Oncol 2023; 41:4520.
          </a>
         </li>
         <li class="breakAll">
          Chittoria N, Zhu H, Choueiri TK, et al. Outcome of metastatic sarcomatoid renal cell carcinoma (sRCC): Results from the International mRCC Database Consortium. ASCO Meeting Abstracts 2013; 31:4565.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carthon BC, Kim SE, McDermott DF, et al. Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808. Clin Genitourin Cancer 2023; 21:546.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shuch B, Said J, La Rochelle JC, et al. Cytoreductive nephrectomy for kidney cancer with sarcomatoid histology--is up-front resection indicated and, if not, is it avoidable? J Urol 2009; 182:2164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haas NB, Lin X, Manola J, et al. A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol 2012; 29:761.
          </a>
         </li>
         <li class="breakAll">
          Michaelson MD, McDermott DF, Atkins MB, et al. Combination of antiangiogenic therapy and cytotoxic chemotherapy for sarcomatoid renal cell carcinoma. ASCO Meeting Abstracts 2013; 31:4512.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fujiwara Y, Kiura K, Tabata M, et al. Remarkable shrinkage of sarcomatoid renal cell carcinoma with single-agent gemcitabine. Anticancer Drugs 2008; 19:431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dutcher JP, Nanus D. Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy. Med Oncol 2011; 28:1530.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Escudier B, Droz JP, Rolland F, et al. Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers. J Urol 2002; 168:959.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michaelson MD, McKay RR, Werner L, et al. Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Cancer 2015; 121:3435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pal SK, Albiges L, Tomczak P, et al. Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial. Lancet 2023; 402:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sun M, De Velasco G, Brastianos PK, et al. The Development of Brain Metastases in Patients with Renal Cell Carcinoma: Epidemiologic Trends, Survival, and Clinical Risk Factors Using a Population-based Cohort. Eur Urol Focus 2019; 5:474.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 128561 Version 19.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : WHO classification of tumours of the urinary system and male genital organs, Moch H, Humphrey PA, Ulbright TM, Reuter VE (Eds), World Health Organization, Lyon 2016.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24025520" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11859199" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33547292" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25450036" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11224597" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15087662" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33051619" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Sarcomatoid renal cell carcinoma: biology, natural history and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26004164" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31382581" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : MiT Family Translocation Renal Cell Carcinoma: from the Early Descriptions to the Current Knowledge.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11743277" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32712550" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29562145" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31427204" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32873572" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36549781" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Nivolumab + cabozantinib (NIVO+CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Efficacy and biomarker analysis of patients (pts) with advanced renal cell carcinoma (aRCC) with sarcomatoid histology (sRCC): Subgroup analysis from the phase III JAVELIN renal 101 trial of first-line avelumab plus axitinib (A + Ax) vs sunitinib (S)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32654802" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33529051" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33529058" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Efficacy of first-line (1L) immunotherapy (IO)-based regimens in patients with sarcomatoid and/or rhabdoid (S/R) metastatic non-clear cell renal cell carcinoma (nccRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37451291" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31721643" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with variant histologies (RCCvh)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with variant histologies (RCCvh)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37455214" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19758641" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Cytoreductive nephrectomy for kidney cancer with sarcomatoid histology--is up-front resection indicated and, if not, is it avoidable?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21298497" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21298497" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18454054" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Remarkable shrinkage of sarcomatoid renal cell carcinoma with single-agent gemcitabine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20717755" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12187199" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26058385" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37290461" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29311016" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : The Development of Brain Metastases in Patients with Renal Cell Carcinoma: Epidemiologic Trends, Survival, and Clinical Risk Factors Using a Population-based Cohort.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
